| Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Secondary to Optic Nerve Head Drusen. |
|
Ka Hee Park |
|
Nune Eye Hospital, Seoul, Korea. ophkh@hanmail.net |
| 맥락막신생혈관을 동반한 시신경유두 드루젠에서 항혈관내피세포성장인자주입술 |
|
박가희 |
|
누네안과병원 |
Correspondence:
Ka Hee Park,
Email: ophkh@hanmail.net
|
|
Received: 16 September 2019 • Revised: 24 October 2019 • Accepted: 6 December 2019 |
| Abstract |
PURPOSE
To describe a patient with optic nerve head drusen who showed improved retinal hemorrhage and visual acuity following intravitreal anti-vascular endothelial growth factor (bevacizumab) injection. CASE SUMMARY: A 53-year-old woman with no underlying disease presented with sudden vision loss in her left eye. Her best-corrected visual acuity was 1.0 in the right eye and 0.8 in the left eye; the intraocular pressure was 15 mmHg in both eyes. Anterior segment examination revealed no abnormal findings. Fundus examination showed subretinal hemorrhage and serous retinal detachment in the left eye. Fluorescein angiography and indocyanine green fundus examination revealed hyperfluorescence near the optic disc. The patient was diagnosed with choroidal neovascularization of the left eye secondary to optic nerve head drusen; intravitreal bevacizumab injection was then performed. Three weeks later, the patient showed improved retinal hemorrhage. CONCLUSIONS: Intravitreal anti-vascular endothelial growth factor injection may be an effective treatment for choroidal neovascularization associated with optic nerve head drusen. |
| Key Words:
Anti-vascular endothelial growth factor;Bevacizumab;Choroidal neovascularization;Intravitreal injection;Optic nerve head drusen |
PDF Links
Full text via DOI
Download Citation
